Web Results

www.delawarelitigation.com/uploads/file/intA4.PDF

May 12, 2009 ... Morse, Esquire, Elena C. Norman, Esquire, Emily V. Burton, Esquire, YOUNG ... Defendant Amylin Pharmaceuticals, Inc. is a publicly traded Delaware ..... L.L.C. et al. ... 16 Amylin Pharmaceuticals, Inc., Definitive Proxy Statement of Carl C. Icahn et al. ... (S.D.N.Y. 2001) (citing U.S. Trust Co. of New York v.

www.lexislegalnews.com/articles/11041/plaintiffs-tell-9th-circuit-incretin-mimetic-mdl-court-got-preemption-law-wrong

Sep 8, 2016 ... Merck Sharp & Dohme Corp., et al., No. ... Byetta brand exenatide, made by defendant Amylin Pharmaceuticals LLC and co-promoted by ... case law, including the U.S. Supreme Court's drug preemption ruling in Wyeth v. ... of DLA Piper in Philadelphia; and Christopher Young of DLA Piper in San Diego. × ...

www.jpml.uscourts.gov/sites/jpml/files/MDL-2452-Initial_Transfer-07-13.pdf

Aug 26, 2013 ... Ralph Thibodeaux v. Amylin Pharmaceuticals, LLC, et al., C.A. No. ... Jerome Goldwire, et al. v. Merck & Co., Inc., et ... Vernie Young v. Amylin ...

www.sciencedirect.com/science/article/pii/S0168822716000073

Jan 9, 2016 ... PPG reduction was greater in Asians (P < 0.0001 vs Whites) for ... lower body mass index (BMI) and in young and middle-aged adults [1]. ...... Drucker et al. ... funded by Amylin Pharmaceuticals LLC and Eli Lilly and Company.

www.law.du.edu/documents/corporate-governance/governance-cases/San-Antonio-Public-Version-of-Appellant-Opening-Brief.PDF

F. Amylin's Board Uses the Proxy Puts to Coerce the Vote ............ 13. G. The Partial ..... Related World Market Center, LLC,. 922 A.2d 417 (Del. .... RiskMetrics Group, Inc, Amylin Pharmaceuticals Inc. (AMLN): “Poison Put”. Litigation ..... 2 See, e. g., Joseph A. Fields et al., Coupon Resets Versus Poison Paris: The. Valuaiion of ...

www.bayardlaw.com/practices/business-practices/corporate-litigation

Amylin Pharmaceuticals, Inc., 2009 WL 4351698 (Del. Ch.) Four Seasons Resort Estates Homeowners Association Limited v. Hotel Equity Fund V, LLC, et al.

onlinelibrary.wiley.com/doi/10.1111/dom.12237/pdf

Correspondence to: David G. Parkes, PhD, Amylin Pharmaceuticals, LLC, 9625 Towne. Centre Drive, San ... lower with exenatide versus dapagliflozin (29.1±1.8 vs. A. B. C. D .... Han et al. reported that oral dapagliflozin produced a 400-fold increase in .... Copley K, McCowen K, Hiles R, Nielsen LL, Young A, Parkes DG.

sullcrom.com/siteFiles/Publications/SC_Publication_San_Antonio_Fire_Police_Pension_Fund_v._Amylin_Pharmaceuticals_Inc.pdf

Jun 12, 2009 ... Amylin Pharmaceuticals, Inc., interpreting a common trust indenture ... Capital Management, L.L.C. (“Eastbourne”) notified Amylin of its intention ...

onlinelibrary.wiley.com/doi/10.1111/dom.12504/pdf

amylin analogue, is approved by the US Food and Drug Admin- istration to ... treatment effect tests (active vs placebo) were conducted at a two-sided ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC4445788

May 18, 2015 ... In a study by Fineman et al,32 37% of exenatide-treated patients ... Squibb and OK was an employee of Amylin Pharmaceuticals, LLC, at the ...